Edward Wild
#104,597
Most Influential Person Now
British neurologist and neuroscientist in the field of Huntington’s disease
Edward Wild 's AcademicInfluence.com Rankings
Edward Wild medical Degrees
Medical
#3623
World Rank
#4107
Historical Rank
Neurology
#335
World Rank
#430
Historical Rank
Edward Wild biology Degrees
Biology
#14355
World Rank
#18080
Historical Rank
Neuroscience
#2605
World Rank
#2675
Historical Rank
Download Badge
Medical Biology
Why Is Edward Wild Influential?
(Suggest an Edit or Addition)According to Wikipedia, Edward Wild, also known as Ed Wild, is a British neurologist and neuroscientist in the field of Huntington's disease and an advocate for scientific outreach to the public. He co-founded the Huntington's research news platform HDBuzz in 2010. He is a professor of neurology at UCL Institute of Neurology and is an associate director of the UCL Huntington's Disease Centre. He is also a consultant neurologist at the National Hospital for Neurology and Neurosurgery in London.
Edward Wild 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Huntington disease: natural history, biomarkers and prospects for therapeutics (2014) (754)
- Huntington disease (2015) (580)
- A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease (2008) (559)
- Targeting Huntingtin Expression in Patients with Huntington's Disease. (2019) (393)
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. (2019) (379)
- Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis (2017) (224)
- Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. (2007) (220)
- Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) (208)
- Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) (208)
- Rapid eye movement sleep disturbances in Huntington disease. (2008) (205)
- Therapies targeting DNA and RNA in Huntington's disease (2017) (204)
- Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY (2011) (186)
- Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. (2015) (185)
- C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies (2014) (168)
- Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities (2020) (154)
- Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. (2012) (130)
- Targets for future clinical trials in Huntington's disease: What's in the pipeline? (2014) (127)
- Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease (2011) (126)
- Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood (2007) (125)
- Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease (2011) (116)
- Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. (2008) (116)
- Huntington's disease phenocopies are clinically and genetically heterogeneous (2008) (115)
- The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study (2009) (114)
- Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease (2018) (103)
- Abnormal peripheral chemokine profile in Huntington’s disease (2011) (102)
- Defective emotion recognition in early HD is neuropsychologically and anatomically generic (2008) (102)
- Huntington's disease phenocopy syndromes (2007) (84)
- MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1 (2019) (82)
- Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study (2010) (82)
- Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis (2020) (81)
- Whole‐brain atrophy as a measure of progression in premanifest and early Huntington's disease (2009) (62)
- The differential diagnosis of chorea (2007) (62)
- Neurofilament light protein in blood predicts regional atrophy in Huntington disease (2018) (53)
- Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington's disease (2009) (52)
- Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease (2009) (51)
- Cerebrospinal Fluid Biomarkers for Huntington's Disease. (2016) (51)
- Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease (2016) (50)
- Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease (2016) (50)
- Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease (2020) (42)
- Harnessing Immune Alterations in Neurodegenerative Diseases (2009) (42)
- Huntington’s Disease Clinical Trials Corner: February 2018 (2018) (41)
- Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins? (2017) (41)
- Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice (2017) (39)
- Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay (2017) (39)
- Huntington’s Disease Clinical Trials Corner: June 2019 (2019) (38)
- Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series (2018) (32)
- George Huntington: a legacy of inquiry, empathy and hope (2016) (30)
- Clinical Trials Corner: September 2017 (2017) (30)
- Fluid and imaging biomarkers for Huntington's disease (2019) (29)
- Serial volumetric MRI in Parkinsonian disorders (2009) (26)
- Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease (2018) (26)
- Déjà vu in neurology (2005) (26)
- NMDA receptor gene variations as modifiers in Huntington disease: a replication study (2011) (24)
- JAK/STAT Signalling in Huntington’s Disease Immune Cells (2013) (22)
- Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities (2022) (22)
- Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease (2020) (22)
- Rate and acceleration of whole‐brain atrophy in premanifest and early Huntington's disease (2010) (20)
- Predict-HD and the future of therapeutic trials (2006) (20)
- Biofluid Biomarkers in Huntington's Disease. (2018) (20)
- Huntington's Disease Clinical Trials Corner: January 2019. (2019) (19)
- Huntington's disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization. (2021) (18)
- Immune markers for Huntington’s disease? (2008) (18)
- Plasma neurofilament heavy chain levels in Huntington's disease (2007) (18)
- Huntington’s Disease Clinical Trials Corner: August 2018 (2018) (17)
- Premanifest and early Huntington's disease (2014) (15)
- The use of wearable/portable digital sensors in Huntington's disease: A systematic review (2021) (15)
- Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease” (2017) (14)
- Biomarkers for Huntington's disease. (2008) (14)
- Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays (2017) (13)
- Huntington's Disease Clinical Trials Corner: March 2020. (2020) (13)
- Biomarkers for Huntington's disease: an update. (2012) (12)
- Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes (2019) (12)
- Observing Huntingtons Disease: the European Huntingtons Disease Networks REGISTRY (2010) (10)
- Vasculitic presentation of staphylococcal meningitis. (2007) (10)
- Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease (2020) (9)
- Characterizing White Matter in Huntington's Disease (2019) (9)
- Huntington's Disease: The Most Curable Incurable Brain Disorder? (2016) (9)
- Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease (2021) (8)
- Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington's disease: the prospective HD-CSF study (2020) (8)
- One decade ago, one decade ahead in huntington's disease (2019) (8)
- Nonlinear Elastic Spline Registration: Evaluation with Longitudinal Huntington's Disease Data (2010) (7)
- Correction: Therapies targeting DNA and RNA in Huntington's disease (vol 16, pg 837, 2017) (2017) (6)
- Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b/2a Studies of WVE-120101 and WVE-120102 in Patients with Huntington’s Disease (P2.006) (2017) (6)
- HDBuzz: empowering patients through accessible education. (2012) (6)
- REM sleep disturbances in huntington disease (2007) (6)
- J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington’s disease, results of the first htt-lowering drug trial (2018) (6)
- Huntington’s Disease Look-alikes (2013) (6)
- Huntington's disease clinical trials corner: April 2022. (2022) (5)
- Psychogenic non-epileptic seizures in early Huntington's disease (2016) (5)
- The Evaluation of Antiperspirant Efficacy--Influence of Certain Variables (1974) (5)
- Neuropsychiatric comorbidities in Huntington’s and Parkinson’s Disease: A United States claims database analysis (2020) (5)
- Abstracts from HSG 2019 (2019) (4)
- QUANTIFYING MUTANT HUNTINGTIN IN HUNTINGTON'S DISEASE CSF (2014) (4)
- Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease (2020) (4)
- The Digital-HD study: Smartphone-Based Remote Testing to Assess Cognitive and Motor Symptoms in Huntington’s Disease (1816) (2020) (4)
- Thyrotoxic periodic paralysis in a Maori patient. (2004) (4)
- F59 Huntington’s disease young adult study (HD-YAS) (2018) (4)
- F61 Digital, high-frequency, long-term monitoring of motor and non-motor symptoms in huntington’s disease (hd) patients (2018) (4)
- K11 C9orf72 Expansions Are The Most Common Genetic Cause Of Huntington’s Disease Phenocopy Presentations In A Uk Cohort (2014) (3)
- Signalling in Huntington ' s Disease Immune Cells (2014) (3)
- Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children (2022) (3)
- Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource. (2022) (2)
- Natural history and burden of Huntington's disease in the UK: A population‐based cohort study (2022) (2)
- Safety and feasibility of research lumbar puncture in Huntington's disease: the HDClarity cohort and bioresource (2021) (2)
- Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI (2019) (2)
- Upcoming Meetings Related to Huntington's Disease. (2018) (2)
- A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease (2019) (2)
- expansions are the most common genetic cause of Huntington ’ s disease phenocopies (2017) (2)
- Huntington's Disease Clinical Trials Corner: November 2022. (2022) (1)
- A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study (2022) (1)
- CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy‐like Phenotype (2022) (1)
- Genetic causes of dementia (2007) (1)
- D21 Analysis of blood and CSF biomarkers in mouse models of Huntington’s disease (2022) (1)
- Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting. (2021) (1)
- Perinatal insults and neurodevelopmental disorders may impact age of diagnosis of Huntington’s disease (2018) (1)
- Ghost Pills: A Case Report. (2017) (1)
- D1 HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for huntington’s disease (2016) (1)
- P3-377: A novel pathogenic pathway of immune activation detectable before cinical onset in Huntington's disease (2008) (1)
- Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice (2017) (1)
- Huntington's disease: fighting on many fronts. (2012) (1)
- Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis (2018) (1)
- PND60 Prevalence and Incidence of Huntington's Disease in the UK (2000–2018): A UK-Based Primary Care Study (2020) (0)
- 241 Intrathecal antisense oligonucleotide delivery in HD: experience from RG6042 programme and best practice considerations (2022) (0)
- D10 Neurofilament light protein in blood predicts regional atrophy in huntington’s disease (2018) (0)
- Huntington's Disease and Other Choreas (2017) (0)
- F10 Environmental modifiers of huntington’s disease: using propensity scores and outcome analyses to identify causal links (2018) (0)
- A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer’s disease (2023) (0)
- You should know you're a medic - Do people who crack their knuckles get arthritis? (2001) (0)
- Lumbar puncture safety and tolerability in premanifest and manifest Huntington’s disease: a multi-analysis cross-sectional study (2022) (0)
- P0500 / #2092: CHRONIC CRITICAL ILLNESS IN PEDIATRIC INTENSIVE CARE (OCTOPUS STUDY): PICU RESOURCE USE AND NURSING WORKLOAD (2021) (0)
- Identification and evaluation of biomarkers for Huntington’s disease (2009) (0)
- Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. (2010) (0)
- Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease (2022) (0)
- F13 Safety and tolerability of lumbar punctures (LP) procedure in patients with huntington’s disease (2021) (0)
- D4 Prediction of huntington’s disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death (2016) (0)
- Neurofilament light protein as a blood biomarker for Huntington's disease in children (2021) (0)
- Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease (2018) (0)
- F05 Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis (2021) (0)
- Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease Authors: (2020) (0)
- Poly ADP-Ribose Signaling is Dysregulated in Huntington’s Disease Patients (2022) (0)
- E07 Cerebrospinal fluid flow dynamics in huntington’s disease using phase contrast MRI: a pilot cross-sectional study (2018) (0)
- Cerebrospinal fluid flow dynamics in Huntington’s disease using phase contrast MRI: a pilot cross-sectional study (P6.343) (2018) (0)
- Brain-derived neurotrophic factor in CSF and plasma is not a biomarker for Huntington's disease (2020) (0)
- D08 Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtington’s disease: a retrospective cohort analysis (2018) (0)
- Neuron NeuroView Harnessing Immune Alterations in Neurodegenerative Diseases (2009) (0)
- Longitudinal Evaluation of Magnetic Resonance Spectroscopy Metabolites as Biomarkers in Huntingtons Disease (2021) (0)
- Huntington's Disease and Dementia (2002) (0)
- Longitudinal Evaluation of Magnetic Resonance Spectroscopy Metabolites as Biomarkers in Huntington’s Disease Running Title: MRS Metabolites in Huntington’s Disease (2021) (0)
- K4 The cost and value of a huntington’s disease multidisciplinary team meeting (2016) (0)
- D06 Influencing Huntington’s disease monitoring and therapeutic development with remote quantification of blood neurofilament light protein (2022) (0)
- Physician perception versus true efficacy of tetrabenazine for Huntington’s disease (2018) (0)
- ACNR MJ07:Layout 1 (2007) (0)
- F05 Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression (2012) (0)
- F06 A critical evaluation of inflammatory markers in Huntington's disease plasma (2012) (0)
- Neurogenetics: Huntington's disease (2012) (0)
- D01 Quantification Of Huntingtin Species In Huntington’s Disease Patient Leukocytes Using Electrochemiluminescence Immunoassays (2014) (0)
- J9 Probing huntington’s disease phenocopy syndromes with next-generation sequencing (2016) (0)
- Huntington’s disease look-alike syndromes (2013) (0)
- Huntington Study Group Abstracts 2020 (2020) (0)
- Huntington’s disease phenocopy syndromes revisited: a clinical comparison and next-generation sequencing exploration (2022) (0)
- P0469 / #762: CHRONIC CRITICAL ILLNESS IN PEDIATRIC INTENSIVE CARE IN SWITZERLAND (OCTOPUS): CHILDREN’ CARE CHARACTERISTICS AND NURSING WORKLOAD (2021) (0)
- F74 Origin-hd: genetic modifiers of htt cag intergenerational repeat instability in male hdgecs (2018) (0)
- The neurological significance of deja vu (2006) (0)
- E05 Longitudinal evaluation of magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease (2022) (0)
- The adequacy of outpatient child psychiatric facilities? (1975) (0)
- D09 Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntington’s disease: the hd-csf study (2018) (0)
- PO002 Bacterial meningitis with myelopathy and cranial neuropathy (2017) (0)
- D08 Elevated GFAP and UCHL-1 in plasma and CSF in HD (2022) (0)
This paper list is powered by the following services:
Other Resources About Edward Wild
What Schools Are Affiliated With Edward Wild ?
Edward Wild is affiliated with the following schools:
